Ileana Rodicio, MD
Allergy & Immunology · Miami, FLNPI 1689638629
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,071 of the $24,355 with a category attached, or 82.4%. 31 manufacturers reported payments, led by Sanofi at 24.1% of the total. 2025 is the largest year on record at $6,618, 2.8 times the $2,372 reported in 2019.
Across 761 payments — averaging $32.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- AstraZeneca$6K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Amgen$1K
- plus $5K from 25 others
Across 358 payments — averaging $10,438 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$1.1M
- Novartis$821K
- GSK$723K
- Amphastar Pharmaceuticals, Inc.$436K
- Eli Lilly$281K
- AstraZeneca$201K
- plus $131K from 3 others
What the payments were for
- Consulting fees$4,04017%
- Travel & lodging$830%
- Food & beverage$20,07182%
- Education$1611%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 80 | $5,866 |
| AstraZeneca | 197 | $5,685 |
| GSK | 119 | $2,799 |
| Regeneron Healthcare Solutions, Inc. | 67 | $2,216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 52 | $1,437 |
| Amgen(2 entities) | 51 | $1,087 |
| Genentech USA, Inc. | 30 | $810 |
| Optinose US, Inc. | 19 | $705 |
| Pharming Healthcare, Inc. | 18 | $550 |
| CSL Behring | 16 | $435 |
| Grifols USA, LLC | 22 | $428 |
| Novartis | 14 | $420 |
| Pfizer | 12 | $245 |
| Galderma Laboratories, L.p. | 4 | $216 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $174 |
| Lilly USA, LLC | 5 | $167 |
| Biocryst US Sales Co., LLC | 7 | $165 |
| Boehringer Ingelheim | 8 | $159 |
| ADMA Biomanufacturing LLC | 2 | $149 |
| Teva Pharmaceuticals USA, Inc. | 8 | $141 |
| Shire North American Group Inc | 7 | $118 |
| Alk-abello, Inc | 6 | $113 |
| AbbVie | 3 | $74 |
| Octapharma USA, Inc. | 2 | $51 |
| Hikma Pharmaceuticals USA | 2 | $32 |
| Ionis Pharmaceuticals, Inc. | 1 | $27 |
| Blueprint Medicines Corporation | 1 | $26 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| Kaleo, Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Cycle Pharmaceuticals Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,355 in reported general payments places this provider in the 85th percentile of 204 allergy & immunology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 42 | $145,945 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $72,197 |
| XolairOmalizumab | 24 | $69,969 |
| FasenraBenralizumab | 11 | $59,948 |
| TezspireTezepelumab-Ekko | 13 | $55,280 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 16 | $38,038 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 52 | $34,754 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $10,349 |
| Azelastine Hcl | 229 | $5,898 |
| Fluocinolone Acetonide | 88 | $5,396 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 43 | $5,386 |
| SymbicortBudesonide/Formoterol Fumarate | 16 | $3,625 |
| Epinephrine | 17 | $3,340 |
| Fluticasone Propionate | 214 | $2,494 |
| Hydroxyzine Hcl | 150 | $2,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFasenra, Tezspire, Breztri Aerosphere, Symbicort | $5,685 | $153,60692 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $2,799 | $82,546124 claims |
| PfizerOctagam | $245 | $38,03816 claims |
| Hikma Pharmaceuticals USAEpinephrine | $32 | $3,34017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 204 allergy & immunology providers in Florida.
Other allergy & immunology in Miami
- Nina RamirezMiami$833K
- Neil GershmanMiami$18K
- Viviana SirvenMiami$12K
- Jaime AlvarezMiami$11K
- Rolando NunezMiami$11K
- Dennis LedfordTampa$1.2M
- Thomas WestbrookPensacola$810K
- Shahnaz FattehPlantation$677K
- Thomas CasaleTampa$382K
- Thomas JohnsonGainesville$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.